BioSpace News Archive

Bio-Tissue, Inc., a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today that its parent company TissueTech had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2 study using morselized Cryopreserved Amniotic Membrane (CAM) and Cryopreserved Umbilical Cord (CUC) Investigational New Drug

The Center for Breakthrough Medicines (CBM), an end-to-end cell and gene therapy (CGT) contract development and manufacturing organization and provider of testing solutions located at Discovery Labs, has completed the appointments of four senior leadership positions

SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced that it has agreed to sell 1,152,628 Units to certain institutional and accredited investors in a private placement at an offering price of $7.07 per Unit.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, is pleased to announce it has completed recruitment of Cohort 1 for its upcoming first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.

Twenty-one scientists from 14 universities and life science companies have formed the Consortium of Scientists for Pandemic Preparedness (CSPP) to combat current challenges in the COVID19 pandemic and create therapeutic, diagnostic and vaccine products to help protect against future outbreaks.

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months and full year ended December 31, 2020.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2020 financial results and provided a corporate update.

Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced today that it will report second quarter 2021 financial results on Monday, March 15, 2021, after the market close

Assertio Holdings, Inc. announced that Dan Peisert, President and Chief Executive Officer of Assertio, will present at and participate in investor meetings at the 33rd Annual Roth Conference, held virtually, on Monday, March 15, 2021.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol, today announced that Atabak Mokari has joined the company as Chief Financial Officer.